secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001193125-25-314728
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics prices $175M upsized public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Priced underwritten offering of 11,851,853 shares at $13.50/share and pre-funded warrants for 1,111,193 shares at $13.499 each.
- Gross proceeds of $175M; net proceeds estimated at $164.1M (or $188.1M if underwriter option exercised).
- Offering upsized; underwriters granted 30-day option to purchase up to 1,944,456 additional shares.
- Net proceeds to fund general corporate purposes, including R&D, clinical trials, and potential acquisitions.
- Closing expected on or about December 11, 2025, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312525314728/0001193125-25-314728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312525314728/fulc-20251210.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-314728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer